Symbols / KMDA Stock $8.27 -1.08% Kamada Ltd.

Healthcare • Drug Manufacturers - Specialty & Generic • Israel • NMS
KMDA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Stock Fundamentals
Scroll to Statements
Market Cap 478.14M Enterprise Value 418.35M Income 20.20M Sales 180.46M Book/sh 4.66 Cash/sh 1.31
Dividend Yield 2.99% Payout 0.00% Employees 462 IPO — P/E 23.63 Forward P/E 13.94
PEG 0.61 P/S 2.65 P/B 1.77 P/C — EV/EBITDA 10.59 EV/Sales 2.32
Quick Ratio 2.20 Current Ratio 4.07 Debt/Eq 4.30 LT Debt/Eq — EPS (ttm) 0.35 EPS next Y 0.59
EPS Growth -14.10% Revenue Growth 14.50% Earnings 2026-05-13 ROA 4.37% ROE 7.64% ROIC —
Gross Margin 42.34% Oper. Margin 7.95% Profit Margin 11.19% Shs Outstand 57.69M Shs Float 10.82M Short Float 0.52%
Short Ratio 1.96 Short Interest — 52W High 9.35 52W Low 6.35 Beta 0.31 Avg Volume 69.17K
Volume 87.94K Target Price $13.00 Recom Strong_buy Prev Close $8.36 Price $8.27 Change -1.08%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$13.00
Mean price target
2. Current target
$8.27
Latest analyst target
3. DCF / Fair value
$2.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.27
Low
$11.00
High
$15.00
Mean
$13.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-09 main HC Wainwright & Co. Buy → Buy $13
2025-05-15 reit Benchmark Buy → Buy $15
2025-03-21 init Benchmark — → Buy $15
2025-03-06 reit HC Wainwright & Co. Buy → Buy $11
2025-01-10 reit HC Wainwright & Co. Buy → Buy $11
2024-11-14 reit HC Wainwright & Co. Buy → Buy $11
2024-08-15 reit HC Wainwright & Co. Buy → Buy $11
2024-07-03 init Stifel — → Buy $18
2024-05-09 reit HC Wainwright & Co. Buy → Buy $11
2024-03-07 reit HC Wainwright & Co. Buy → Buy $11
2023-11-14 reit HC Wainwright & Co. Buy → Buy $11
2023-08-17 reit HC Wainwright & Co. Buy → Buy $11
2023-05-25 reit HC Wainwright & Co. Buy → Buy $11
2023-03-16 reit HC Wainwright & Co. — → Buy $11
2018-02-02 init Chardan Capital — → Buy $7
2015-11-13 main Jefferies — → Buy $8
2013-06-25 init Jefferies — → Buy $15
2013-06-25 init Morgan Stanley — → Equal-Weight —
2013-06-25 init Oppenheimer — → Outperform $14
News
RSS: Latest KMDA news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
180.46
+12.12%
160.95
+12.93%
142.52
+10.19%
129.34
Operating Revenue
180.46
+12.12%
160.95
+12.93%
142.52
+10.19%
129.34
Cost Of Revenue
104.05
+14.36%
90.99
+4.55%
87.03
+5.32%
82.64
Reconciled Cost Of Revenue
92.47
+14.91%
80.47
+3.92%
77.44
+5.35%
73.51
Gross Profit
76.41
+9.20%
69.97
+26.09%
55.49
+18.81%
46.70
Operating Expense
50.17
+0.52%
49.92
+9.88%
45.43
+7.72%
42.17
Research And Development
12.99
-14.42%
15.19
+8.99%
13.93
+5.78%
13.17
Selling General And Administration
33.84
+9.75%
30.83
+12.33%
27.45
+9.54%
25.06
Selling And Marketing Expense
9.73
-6.67%
10.43
+13.39%
9.20
+0.16%
9.18
General And Administrative Expense
24.11
+18.14%
20.41
+11.80%
18.25
+14.97%
15.88
Salaries And Wages
14.63
+9.73%
13.34
+15.68%
11.53
+17.61%
9.80
Other Gand A
8.09
+37.08%
5.90
+14.36%
5.16
-15.08%
6.08
Other Operating Expenses
—
0.60
-34.60%
0.92
+0.77%
0.91
Total Expenses
154.23
+9.46%
140.90
+6.38%
132.46
+6.13%
124.81
Operating Income
26.23
+30.83%
20.05
+99.23%
10.06
+122.07%
4.53
Total Operating Income As Reported
26.23
+30.83%
20.05
+99.23%
10.06
+122.07%
4.53
EBITDA
39.25
+41.17%
27.80
+23.89%
22.44
+107.59%
10.81
Normalized EBITDA
40.42
+44.90%
27.90
+24.61%
22.39
+112.96%
10.51
Reconciled Depreciation
14.92
+8.04%
13.81
+8.60%
12.71
+4.60%
12.15
EBIT
24.33
+73.87%
13.99
+43.87%
9.73
+823.20%
-1.34
Total Unusual Items
-1.17
-1145.74%
-0.09
-270.91%
0.06
-81.54%
0.30
Total Unusual Items Excluding Goodwill
-1.17
-1145.74%
-0.09
-270.91%
0.06
-81.54%
0.30
Net Income
20.20
+39.66%
14.46
+74.58%
8.28
+456.92%
-2.32
Pretax Income
23.47
+75.99%
13.33
+58.19%
8.43
+473.13%
-2.26
Net Non Operating Interest Income Expense
1.06
-27.50%
1.46
+305.35%
-0.71
+13.73%
-0.82
Interest Expense Non Operating
0.86
+30.91%
0.66
-49.15%
1.30
+42.01%
0.91
Net Interest Income
1.06
-27.50%
1.46
+305.35%
-0.71
+13.73%
-0.82
Interest Expense
0.86
+30.91%
0.66
-49.15%
1.30
+42.01%
0.91
Interest Income Non Operating
1.92
-9.30%
2.12
+260.20%
0.59
+546.15%
0.09
Interest Income
1.92
-9.30%
2.12
+260.20%
0.59
+546.15%
0.09
Other Income Expense
-3.82
+53.24%
-8.18
-783.78%
-0.93
+84.50%
-5.97
Other Non Operating Income Expenses
-2.65
+67.18%
-8.08
-724.59%
-0.98
+84.36%
-6.27
Gain On Sale Of Security
-1.17
-1145.74%
-0.09
-270.91%
0.06
-81.54%
0.30
Tax Provision
3.27
+389.80%
-1.13
-877.93%
0.14
+133.87%
0.06
Tax Rate For Calcs
0.00
-39.43%
0.00
+1236.98%
0.00
-92.52%
0.00
Tax Effect Of Unusual Items
-0.16
-654.50%
-0.02
-2385.08%
0.00
-98.62%
0.07
Net Income Including Noncontrolling Interests
20.20
+39.66%
14.46
+74.58%
8.28
+456.92%
-2.32
Net Income From Continuing Operation Net Minority Interest
20.20
+39.66%
14.46
+74.58%
8.28
+456.92%
-2.32
Net Income From Continuing And Discontinued Operation
20.20
+39.66%
14.46
+74.58%
8.28
+456.92%
-2.32
Net Income Continuous Operations
20.20
+39.66%
14.46
+74.58%
8.28
+456.92%
-2.32
Normalized Income
21.21
+45.90%
14.53
+76.60%
8.23
+422.68%
-2.55
Net Income Common Stockholders
20.20
+39.66%
14.46
+74.58%
8.28
+456.92%
-2.32
Diluted EPS
0.35
+40.00%
0.25
+66.67%
0.15
+400.00%
-0.05
Basic EPS
0.35
+40.00%
0.25
+47.06%
0.17
+440.00%
-0.05
Basic Average Shares
57.71
-0.24%
57.85
+18.47%
48.83
+5.19%
46.42
Diluted Average Shares
57.71
-0.24%
57.85
+7.77%
53.68
+15.63%
46.42
Diluted NI Availto Com Stockholders
20.20
+39.66%
14.46
+74.58%
8.28
+456.92%
-2.32
Depreciation Amortization Depletion Income Statement
3.34
+1.27%
3.30
+5.47%
3.12
+3.17%
3.03
Depreciation And Amortization In Income Statement
3.34
+1.27%
3.30
+5.47%
3.12
+3.17%
3.03
Insurance And Claims
1.39
+18.45%
1.17
-25.22%
1.57
—
Total Other Finance Cost
—
—
0.98
-84.36%
6.27
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
378.71
+1.73%
372.25
+4.89%
354.91
+10.09%
322.38
Current Assets
193.07
+4.73%
184.35
+8.46%
169.96
+22.27%
139.00
Cash Cash Equivalents And Short Term Investments
75.47
-3.78%
78.44
+40.97%
55.64
+62.42%
34.26
Cash And Cash Equivalents
75.47
-3.78%
78.44
+40.97%
55.64
+62.42%
34.26
Cash Equivalents
37.25
-32.65%
55.30
+268.43%
15.01
+427.26%
2.85
Cash Financial
38.22
+65.25%
23.13
-43.07%
40.63
+29.35%
31.41
Other Short Term Investments
—
—
—
—
Receivables
28.84
+24.34%
23.20
+8.97%
21.29
-24.92%
28.36
Accounts Receivable
27.01
+26.27%
21.39
+8.43%
19.73
-27.29%
27.13
Gross Accounts Receivable
27.01
+26.27%
21.39
+8.43%
19.73
-27.29%
27.13
Allowance For Doubtful Accounts Receivable
0.00
0.00
0.00
0.00
Other Receivables
1.84
+1.49%
1.81
+15.81%
1.56
+27.30%
1.23
Inventory
84.94
+7.77%
78.82
-10.92%
88.48
+22.01%
72.52
Raw Materials
34.34
+12.47%
30.54
+7.98%
28.28
+32.60%
21.33
Work In Process
7.03
-23.26%
9.16
+37.76%
6.65
-45.80%
12.28
Finished Goods
35.42
+20.61%
29.37
-30.94%
42.53
+39.75%
30.43
Prepaid Assets
3.62
-5.82%
3.85
-12.67%
4.41
+13.68%
3.88
Hedging Assets Current
0.20
+302.04%
0.05
-67.11%
0.15
0.00
Total Non Current Assets
185.63
-1.21%
187.91
+1.60%
184.94
+0.86%
183.37
Net PPE
50.27
+9.60%
45.86
+27.45%
35.98
+25.27%
28.73
Gross PPE
121.19
+9.45%
110.73
+14.87%
96.39
+13.49%
84.94
Accumulated Depreciation
-70.92
-9.34%
-64.86
-7.37%
-60.41
-7.47%
-56.21
Properties
0.00
0.00
0.00
0.00
Land And Improvements
41.29
+10.64%
37.32
+3.56%
36.04
+2.71%
35.09
Buildings And Improvements
7.59
-7.75%
8.23
+29.37%
6.36
+267.38%
1.73
Machinery Furniture Equipment
61.88
+10.28%
56.11
+10.24%
50.90
+9.36%
46.54
Other Properties
—
0.01
+1400.00%
0.00
-85.71%
0.01
Leases
10.42
+15.23%
9.04
+192.40%
3.09
+97.51%
1.57
Goodwill And Other Intangible Assets
126.41
-4.36%
132.17
-5.56%
139.96
-4.80%
147.01
Goodwill
30.31
+0.00%
30.31
+0.00%
30.31
+0.00%
30.31
Other Intangible Assets
96.10
-5.66%
101.86
-7.10%
109.64
-6.04%
116.70
Non Current Accounts Receivable
7.54
-5.92%
8.02
-5.60%
8.49
+12.12%
7.58
Non Current Deferred Assets
0.00
-100.00%
0.49
0.00
—
Non Current Deferred Taxes Assets
0.00
-100.00%
0.49
0.00
—
Non Current Prepaid Assets
1.42
+3.59%
1.37
+167.84%
0.51
+709.52%
0.06
Other Non Current Assets
30.31
—
-0.00
—
Total Liabilities Net Minority Interest
109.64
-2.79%
112.79
+1.72%
110.89
-24.24%
146.36
Current Liabilities
47.39
-4.04%
49.39
-0.41%
49.59
-34.49%
75.70
Payables And Accrued Expenses
25.08
-11.02%
28.19
+11.21%
25.35
-24.40%
33.53
Payables
23.24
-16.20%
27.73
+11.82%
24.80
-24.65%
32.92
Accounts Payable
23.24
-16.20%
27.73
+11.82%
24.80
-24.65%
32.92
Current Accrued Expenses
1.84
+306.40%
0.45
-16.42%
0.54
-11.00%
0.61
Employee Benefits
0.67
+31.63%
0.51
-18.04%
0.62
-7.59%
0.67
Pensionand Other Post Retirement Benefit Plans Current
10.27
+11.38%
9.22
+22.22%
7.54
+12.85%
6.68
Current Debt And Capital Lease Obligation
2.12
+30.04%
1.63
+17.85%
1.38
-74.65%
5.46
Current Debt
—
—
—
4.44
Other Current Borrowings
—
—
—
4.44
Current Capital Lease Obligation
2.12
+30.04%
1.63
+17.85%
1.38
+36.22%
1.02
Current Deferred Liabilities
0.00
-100.00%
0.17
-47.38%
0.33
+37.71%
0.24
Current Deferred Revenue
0.00
-100.00%
0.17
-47.38%
0.33
+37.71%
0.24
Other Current Liabilities
9.92
-2.53%
10.18
-32.11%
15.00
-49.68%
29.80
Total Non Current Liabilities Net Minority Interest
62.25
-1.82%
63.40
+3.44%
61.29
-13.25%
70.65
Long Term Debt And Capital Lease Obligation
9.44
+0.10%
9.43
+26.79%
7.44
-50.87%
15.14
Long Term Debt
—
—
—
12.96
Long Term Capital Lease Obligation
9.44
+0.10%
9.43
+26.79%
7.44
+241.66%
2.18
Non Current Deferred Liabilities
1.65
0.00
—
0.00
Non Current Deferred Revenue
—
—
—
0.00
Non Current Deferred Taxes Liabilities
1.65
0.00
—
—
Other Non Current Liabilities
50.48
-5.57%
53.46
+0.43%
53.23
-2.93%
54.84
Stockholders Equity
269.07
+3.70%
259.46
+6.33%
244.02
+38.63%
176.02
Common Stock Equity
269.07
+3.70%
259.46
+6.33%
244.02
+38.63%
176.02
Capital Stock
15.08
+0.33%
15.03
+0.05%
15.02
+28.01%
11.73
Common Stock
15.08
+0.33%
15.03
+0.05%
15.02
+28.01%
11.73
Share Issued
57.69
+0.31%
57.51
+0.04%
57.48
+28.21%
44.83
Ordinary Shares Number
57.69
+0.31%
57.51
+0.04%
57.48
+28.21%
44.83
Additional Paid In Capital
268.28
+0.51%
266.93
+0.41%
265.85
+26.30%
210.50
Retained Earnings
-17.07
+33.66%
-25.74
+35.98%
-40.20
+17.09%
-48.48
Gains Losses Not Affecting Retained Earnings
-2.93
+4.78%
-3.08
+0.00%
-3.08
+4.80%
-3.23
Other Equity Adjustments
0.18
+247.06%
0.05
-63.57%
0.14
+259.09%
-0.09
Total Equity Gross Minority Interest
269.07
+3.70%
259.46
+6.33%
244.02
+38.63%
176.02
Total Capitalization
269.07
+3.70%
259.46
+6.33%
244.02
+29.12%
188.98
Working Capital
145.68
+7.95%
134.96
+12.12%
120.37
+90.16%
63.30
Invested Capital
269.07
+3.70%
259.46
+6.33%
244.02
+26.16%
193.43
Total Debt
11.56
+4.51%
11.06
+25.39%
8.82
-57.17%
20.60
Net Debt
—
—
—
—
Capital Lease Obligations
11.56
+4.51%
11.06
+25.39%
8.82
+176.29%
3.19
Net Tangible Assets
142.66
+12.07%
127.29
+22.32%
104.07
+258.71%
29.01
Tangible Book Value
142.66
+12.07%
127.29
+22.32%
104.07
+258.71%
29.01
Foreign Currency Translation Adjustments
-3.49
+0.00%
-3.49
+0.00%
-3.49
+0.00%
-3.49
Minimum Pension Liabilities
0.39
+5.77%
0.36
+32.36%
0.28
-20.98%
0.35
Other Equity Interest
5.71
-9.58%
6.32
-1.73%
6.43
+16.75%
5.50
Other Inventories
8.14
-16.47%
9.75
-11.54%
11.02
+29.87%
8.49
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
25.49
-46.44%
47.59
+1002.99%
4.32
-84.91%
28.59
Cash Flow From Continuing Operating Activities
25.49
-46.44%
47.59
+1002.99%
4.32
-84.91%
28.59
Net Income From Continuing Operations
20.20
+39.66%
14.46
+74.58%
8.28
+456.92%
-2.32
Depreciation Amortization Depletion
14.92
+8.04%
13.81
+8.60%
12.71
+4.60%
12.15
Depreciation
—
—
12.71
+4.60%
12.15
Depreciation And Amortization
14.92
+8.04%
13.81
+8.60%
12.71
+4.60%
12.15
Other Non Cash Items
2.77
-58.82%
6.72
+310.83%
1.64
-75.92%
6.79
Pension And Employee Benefit Expense
0.18
+251.92%
0.05
+141.60%
-0.12
-12.61%
-0.11
Stock Based Compensation
0.84
-3.32%
0.87
-33.49%
1.31
+13.96%
1.15
Deferred Tax
3.27
+389.80%
-1.13
-877.93%
0.14
+133.87%
0.06
Deferred Income Tax
3.27
+389.80%
-1.13
-877.93%
0.14
+133.87%
0.06
Operating Gains Losses
0.17
+177.78%
0.06
+148.46%
-0.13
-17.12%
-0.11
Gain Loss On Sale Of PPE
-0.01
-172.73%
0.01
+320.00%
-0.01
0.00
Change In Working Capital
-17.68
-254.93%
11.41
+162.70%
-18.20
-256.25%
11.65
Change In Receivables
-5.47
-502.09%
-0.91
-109.56%
9.50
+67.09%
5.68
Changes In Account Receivables
-5.41
-173.50%
-1.98
-125.23%
7.83
+3.05%
7.60
Change In Inventory
-6.12
-163.40%
9.66
+149.05%
-19.69
-1347.02%
-1.36
Change In Payables And Accrued Expense
-5.92
-324.33%
2.64
+132.50%
-8.12
-210.55%
7.34
Change In Payable
-5.92
-324.33%
2.64
+132.50%
-8.12
-210.55%
7.34
Change In Account Payable
-6.87
-660.36%
1.23
+113.80%
-8.88
-225.94%
7.05
Change In Other Working Capital
-0.17
-843.48%
0.02
-79.65%
0.11
+665.00%
-0.02
Investing Cash Flow
-9.84
+8.39%
-10.74
-83.79%
-5.84
-54.41%
-3.78
Cash Flow From Continuing Investing Activities
-9.84
+8.39%
-10.74
-83.79%
-5.84
-54.41%
-3.78
Net PPE Purchase And Sale
-9.84
+8.39%
-10.74
-83.79%
-5.84
-54.41%
-3.78
Purchase Of PPE
-9.85
+8.32%
-10.74
-83.59%
-5.85
-54.60%
-3.78
Sale Of PPE
0.01
+700.00%
0.00
-85.71%
0.01
0.00
Capital Expenditure
-9.85
+8.32%
-10.74
-83.59%
-5.85
-54.60%
-3.78
Net Investment Purchase And Sale
—
—
0.00
0.00
Sale Of Investment
—
—
—
—
Net Business Purchase And Sale
—
—
—
0.00
Purchase Of Business
—
—
—
0.00
Financing Cash Flow
-18.34
-31.87%
-13.91
-161.34%
22.68
+342.73%
-9.34
Cash Flow From Continuing Financing Activities
-18.34
-31.87%
-13.91
-161.34%
22.68
+342.73%
-9.34
Net Issuance Payments Of Debt
-0.97
+22.30%
-1.25
+93.15%
-18.26
-389.99%
-3.73
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
-0.97
+22.30%
-1.25
+93.15%
-18.26
-389.99%
-3.73
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
-0.97
+22.30%
-1.25
+93.15%
-18.26
-389.99%
-3.73
Net Long Term Debt Issuance
-0.97
+22.30%
-1.25
+93.15%
-18.26
-389.99%
-3.73
Net Common Stock Issuance
0.00
0.00
-100.00%
58.23
0.00
Common Stock Dividend Paid
-11.53
0.00
0.00
—
Cash Dividends Paid
-11.53
0.00
0.00
—
Proceeds From Stock Option Exercised
0.05
+614.29%
0.01
+75.00%
0.00
-55.56%
0.01
Net Other Financing Charges
-5.89
+53.51%
-12.67
+26.78%
-17.30
-207.50%
-5.63
Changes In Cash
-2.69
-111.74%
22.94
+8.48%
21.15
+36.81%
15.46
Effect Of Exchange Rate Changes
-0.27
-82.00%
-0.15
-164.38%
0.23
+9.91%
0.21
Beginning Cash Position
78.44
+40.97%
55.64
+62.42%
34.26
+84.31%
18.59
End Cash Position
75.47
-3.78%
78.44
+40.97%
55.64
+62.42%
34.26
Free Cash Flow
15.64
-57.55%
36.85
+2500.91%
-1.53
-106.19%
24.80
Common Stock Issuance
0.00
0.00
-100.00%
58.23
0.00
Interest Paid CFO
-0.86
-45.45%
-0.59
+51.63%
-1.23
-43.96%
-0.85
Interest Received CFO
1.92
-9.30%
2.12
0.00
-100.00%
0.10
Issuance Of Capital Stock
0.00
0.00
-100.00%
58.23
0.00
Taxes Refund Paid
-0.06
+59.71%
-0.14
+35.94%
-0.22
-502.78%
-0.04
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category